Scholar Rock Holding (SRRK) Enterprise Value (2017 - 2026)
Scholar Rock Holding (SRRK) recorded quarterly Enterprise Value of -$479.9 million in Q1 2026, down 30.57% quarter-over-quarter from -$367.6 million in Q4 2025, and down 31.72% on a YoY basis from -$702.9 million in Q1 2025.
Scholar Rock Holding (SRRK) Enterprise Value (2017 - 2026) Analysis & Trends
Scholar Rock Holding's Enterprise Value history runs 10 years deep, the most recent figure standing at -$479.9 million for Q1 2026.
- In Q1 2026, Enterprise Value fell 31.72% year-over-year to -$479.9 million; the TTM figure through Mar 2026 stood at -$479.9 million (down 31.72% YoY), while the FY2025 annual figure was -$367.6 million, up 15.94% from the prior year.
- Enterprise Value was -$479.9 million for Q1 2026 at Scholar Rock Holding, down from -$367.6 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$139.1 million in Q3 2024 to a low of -$479.9 million in Q1 2026.
- Historically, Enterprise Value has averaged -$302.6 million across 5 years, with a median of -$295.0 million in 2025.
- The sharpest annual moves came in 2024 and 2025: Enterprise Value jumped 36.39% in 2024, then plunged 165.8% in 2025.
- A 5-year view of Enterprise Value shows it stood at -$315.4 million in 2022, then climbed by 11.23% to -$279.9 million in 2023, then slumped by 56.21% to -$437.3 million in 2024, then increased by 15.94% to -$367.6 million in 2025, then plunged by 30.57% to -$479.9 million in 2026.
- The last three Enterprise Value figures came in at -$479.9 million (Q1 2026), -$367.6 million (Q4 2025), and -$369.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | -32.30 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -4.14 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -286.70 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -18.44 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -2.77 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -7.20 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -7.25 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -584.73 Mn |
| 10 | Scholar Rock Holding | 6.03 Bn | 5.55 Bn | - | -479.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -479.94 Mn |
| Dec 31, 2025 | -367.56 Mn |
| Sep 30, 2025 | -369.63 Mn |
| Jun 30, 2025 | -295.01 Mn |
| Mar 31, 2025 | -364.38 Mn |
| Dec 31, 2024 | -437.28 Mn |
| Sep 30, 2024 | -139.07 Mn |
| Jun 30, 2024 | -190.49 Mn |
| Mar 31, 2024 | -238.43 Mn |
| Dec 31, 2023 | -279.94 Mn |
| Sep 30, 2023 | -218.64 Mn |
| Jun 30, 2023 | -248.73 Mn |
| Mar 31, 2023 | -275.28 Mn |
| Dec 31, 2022 | -315.36 Mn |
| Sep 30, 2022 | -343.66 Mn |
| Jun 30, 2022 | -370.69 Mn |
| Mar 31, 2022 | -210.21 Mn |
| Dec 31, 2021 | -252.99 Mn |
| Sep 30, 2021 | -246.44 Mn |
| Jun 30, 2021 | -282.22 Mn |